MentionFox
Home › Executive changes › Arcus Biosciences, Inc.
Leadership changes · RCUS · SEC Form 8-K, Item 5.02

Leadership changes at Arcus Biosciences, Inc. (2026)

Before you join, sell to or invest in Arcus Biosciences, Inc.

MentionFox check on Arcus Biosciences, Inc.: only 1 source on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/arcus-biosciences

Check Arcus Biosciences, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Arcus Biosciences, Inc.?

Who joined and who left Arcus Biosciences, Inc. (RCUS)? 1 departure reported on 2026-03-23, each cited to the company's own filing.

Jennifer Jarrett's departure as Chief Operating Officer of Arcus Biosciences, Inc. was reported, effective March 30, 2026; the filing names no successor. As of November 14, 2026, Arcus Biosciences, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 23, 2026, naming 1 departure (Form 8-K, March 23, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

GILEAD SCIENCES, INC. also filed stake reports on 5 other companies ↓

Sell to companies like Arcus Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
Out (departing)1
Latest filing2026-03-23

Arcus Biosciences, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-23. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Arcus Biosciences, Inc. files it.

Also on the record for Arcus Biosciences, Inc.

DateRecordFigureOur pageSource
August 7, 2026Stake report, Schedule 13D/A, by Gilead Sciences, Inc.24.7% of the class5%+ stakesSource
March 26, 2026Stake report, Schedule 13G/A, by The Vanguard Group—5%+ stakesSource
January 8, 2026Stake report, Schedule 13G/A, by BlackRock, Inc.10.4% of the class5%+ stakesSource
November 14, 2025Stake report, Schedule 13G/A, by Point72 Asset Management, L.P.4.1% of the class5%+ stakesSource
November 5, 2025Stake report, Schedule 13D/A, by GILEAD SCIENCES, INC.25.6% of the class5%+ stakesSource
July 15, 2025Stake report, Schedule 13D/A, by GILEAD SCIENCES, INC.29.7% of the class5%+ stakesSource

Selling to them or working with them? See who runs Arcus Biosciences, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on Arcus Biosciences, Inc. and the records around it.

Arcus Biosciences, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Arcus Biosciences, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Arcus Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Arcus Biosciences, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    7 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-03-23OutChief Operating Officer2026-03-308-K, 2026-03-23

Why did they leave? What the filings say

For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.

Who leads Arcus Biosciences, Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Arcus Biosciences, Inc.?

New leaders reset buying decisions — get the Full Report on Arcus Biosciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Arcus Biosciences, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Chief Operating Officer at Arcus Biosciences, Inc., with the record behind each one.

Find candidates like Chief Operating Officer at Arcus Biosciences, Inc.

Every change, in the filing's words

Filed 2026-03-23 · 8-K

Departing: Jennifer Jarrett, Chief Operating Officer, effective 2026-03-30

On March 17, 2026, Jennifer Jarrett notified Arcus Biosciences, Inc. (the "Company") of her decision to resign from her position as Chief Operating Officer, effective as of March 30, 2026.

Also stated in this filing

  • The Company and Ms. Jarrett entered into a separation agreement pursuant to which Ms. Jarrett will make herself available for periodic advisory services for a period through June 30, 2026.
  • In consideration for such services, the Company agreed to extend the post-termination option exercise period during which she may continue to exercise any vested options to twelve (12) months.
  • The separation agreement also contains a standard release of claims.

Tools for this story

Each opens in a new tab, filled in for Arcus Biosciences, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/arcus-biosciences
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Arcus Biosciences, Inc. executive departure 2026. MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/arcus-biosciences